01.03.2026, 1480 Zeichen

EVN: Austrian utility company EVN reported results for the first quarter of business year 2025/2026. Revenue recorded by the EVN Group rose by 3.3% to EUR 830.7m in the first quarter of 2025/26, above all due to regulatory price effects in the distribution network companies in Lower Austria and Bulgaria. EBITDA declined by 2.2% year-on-year to EUR 247.4m. The high volume of investments led to an increase of 8.4% in scheduled depreciation and amortisation to EUR 94.2m. EBIT was 7.8% lower year-on-year at EUR 153.2m. Generation coefficients both for wind and water were - with the exception of water flows in North Macedonia - clearly below the long-term average and previous year in all markets.
EVN: weekly performance: 1.37%

FACC: Aerospace supplier FACC AG is looking back on a successful 2025 financial year and is consistently continuing its sustainable growth course. Group revenue rose to EUR 984.4 million in the 2025 financial year (2024: EUR 884.5 million). Despite high site costs in Austria due to a sharp increase in personnel and energy costs compared to the global environment, the operating result (EBIT) increased noticeably by 49.4% to EUR 42.3 million. The EBIT margin thus improved from 3.2% to 4.3%. Particularly pleasing: All divisions – Aerostructures, Engines & Nacelles and Cabin Interiors – made a positive contribution to earnings.
FACC: weekly performance: 28.78%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (25/02/2026)

Christian Drastil: Wiener Börse Plausch

Wiener Börse Party #1106: ATX zu Mittag 4 Prozent im Minus, ein fehlendes Listing bzw, warum mir diese Marktphase in die Hände spielt

Bildnachweis

Aktien auf dem Radar:Bawag, FACC, RHI Magnesita, Kapsch TrafficCom, Austriacard Holdings AG, Polytec Group, Rosgix, AT&S, ATX, ATX TR, voestalpine, Porr, ATX NTR, Erste Group, Amag, DO&CO, EuroTeleSites AG, Hutter & Schrantz Stahlbau, Lenzing, OMV, Bajaj Mobility AG, RBI, Rosenbauer, Verbund, Wienerberger, Wolford, BKS Bank Stamm, Oberbank AG Stamm, UBM, Marinomed Biotech, CA Immo.

---